Skip to main content
2024 Guide to Patient Support Services

Amgen

2024 PSS Guide

Amgen SupportPlus

Amgen offers assistance to patients through Amgen SupportPlus Co-Pay Program, and the Amgen Safety Net Foundation. A complete list of Amgen oncology products and their related assistance programs is provided in the Table.

Amgen SupportPlus Co-Pay Program

This program can help your eligible commercially insured patients cover their out-of-pocket prescriptions costs. Eligibility criteria and program maximums apply. See AmgenSupportPlus.com/copay for full Terms and Conditions.

Patients can register for this program by visiting AmgenSupportPlus.com. For more information, call 866-264-2778.

Amgen Safety Net Foundation

This foundation assists patients who are uninsured or their insurance plan excludes the prescribed Amgen medicine or its generic/biosimilar. To apply to the Amgen Safety Net Foundation, visit www.amgensafetynetfoundation.com and select the prescribed medicine.

TABLE Amgen Oncology/Supportive Care Drugs

Drugs
Indications
Patient support programs

Drug
Aranesp (darbepoetin alfa)
Indications
To treat the effects of concomitant myelosuppressive chemotherapy; on initiation, a minimum of 2 additional months of chemotherapy are planned
Patient support programs

Drug
Blincyto (blinatumomab)
Indications
Treatment of adult and pediatric patients with: CD19-positive B-cell precursor acute lymphoblastic leukemia in first or second complete remission with minimal residual disease ≥0.1%; treatment of relapsed or refractory CD19-positive B-cell precursor acute lymphoblastic leukemia
Patient support programs

Drug
Epogen (epoetin alfa)
Indications
To treat the effects of concomitant myelosuppressive chemotherapy; upon initiation, there is a minimum of 2 additional months of planned chemotherapy
Patient support program

Drug
Imlygic (talimogene laherparepvec)
Indications
Local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery
Patient support programs

Drug
Kanjinti (trastuzumab-anns)
Indications
Treatment of HER2-overexpressing breast cancer; treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma; select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product
Patient support programs

Drug
Kyprolis (carfilzomib)
Indications
Treatment of adult patients with relapsed or refractory multiple myeloma after 1 to 3 lines of therapy in combination with lenalidomide and dexamethasone; or dexamethasone; or daratumumab and dexamethasone; or daratumumab and hyaluronidase-fihj and dexamethasone; or isatuximab and dexamethasone; monotherapy for relapsed or refractory multiple myeloma who have received 1 or more lines of therapy
Patient support programs

Drug
Lumakras (sotorasib)
Indications
Treatment of adult patients with KRAS G12C–mutated locally advanced or metastatic NSCLC, as determined by an FDA-approved test, who have received at least 1 prior systemic therapy
Patient support programs

Drug
Mvasi (bevacizumab-awwb)
Indications
Patient support programs

Drug
Neulasta (pegfilgrastim)
Indications
To decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia; to increase survival in patients acutely exposed to myelosuppressive doses of radiation (hematopoietic subsyndrome of acute radiation syndrome)
Patient support programs

Drug
Neupogen (filgrastim)
Indications
Patient support programs

Drug
Nplate (romiplostim)
Indications
Patient support programs

Drug
Prolia (denosumab)
Indications
Increase bone mass (1) in men with prostate cancer receiving androgen-deprivation therapy, or (2) in women with breast cancer receiving adjuvant aromatase inhibitor therapy
Patient support programs

Drug
Riabni (rituximab-arrx)
Indications
Patient support programs

Drug
Vectibix (panitumumab)
Indications
Treatment of wild-type RAS metastatic colorectal cancer as either first-line in combination with FOLFOX or as monotherapy following disease progression after prior treatment with chemotherapy
Patient support programs

Drug
Xgeva (denosumab)
Indications
To prevent skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors; treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity; treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy
Patient support programs

Kyprolis (carfilzomib) Indications

Relapsed or refractory multiple myeloma after 1 to 3 lines of therapy in combination with lenalidomide and dexamethasone; or dexamethasone; or daratumumab and dexamethasone; or daratumumab and hyaluronidase-fihj and dexamethasone; or isatuximab and dexamethasone; monotherapy for relapsed or refractory multiple myeloma who have received 1 or more lines of therapy

Mvasi (bevacizumab-awwb) Indications

Treatment of:
  • Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment.
  • Metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen.
  • Unresectable, locally advanced, recurrent or metastatic non-squamous non–small cell lung cancer, in combination with carboplatin and paclitaxel for first-line treatment.
  • Recurrent glioblastoma in adults.
  • Metastatic renal cell carcinoma in combination with interferon-alfa.
  • Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxel and topotecan.
  • Epithelial ovarian, fallopian tube, or primary peritoneal cancer:
    • in combination with carboplatin and paclitaxel, followed by MVASI as a single agent, for stage III or IV disease following initial surgical resection
    • in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens
    • in combination with carboplatin and paclitaxel or carboplatin and gemcitabine, followed by MVASI as a single agent, for platinum-sensitive recurrent disease

Neupogen (filgrastim)

To decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever; to reduce the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia; to reduce the duration of neutropenia and neutropenia-related clinical sequelae in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation; to mobilize autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis; to increase survival in patients acutely exposed to myelosuppressive doses of radiation (hematopoietic syndrome of acute radiation syndrome)

Nplate (romiplostim) Indications

Treatment of adult patients with immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy; treatment of pediatric patients ≥1 year of age with ITP for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy; to increase survival in adults and in pediatric patients (including term neonates) acutely exposed to myelosuppressive doses of radiation (hematopoietic syndrome of acute radiation syndrome)

Riabni (rituximab-arrx) Indications

Treatment of:
Adult patients with non-Hodgkin lymphoma (NHL), including relapsed or refractory, low-grade or follicular, CD20-positive B-cell NHL as a single agent; previously untreated follicular, CD20-positive, B-cell NHL in combination with first-line chemotherapy; in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy; nonprogressing, low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone chemotherapy; previously untreated diffuse large B-cell, CD20-positive NHL in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone or other anthracycline-based chemotherapy regimens; treatment of adult patients with chronic lymphocytic leukemia (CLL), including previously untreated and previously treated CD20-positive CLL in combination with fludarabine and cyclophosphamide